104 related articles for article (PubMed ID: 38723556)
1. Development of a reliable cell-based reporter gene assay to measure the bioactivity of anti-HER2 therapeutic antibodies.
Zhao X; Qian W; Hou S; Wu Y; Guo H; Xu J; Zhang D; Li J; Fu R; Xu M; Wang F
J Pharm Biomed Anal; 2024 Aug; 245():116185. PubMed ID: 38723556
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of a reporter gene assay to determine the bioactivity of anti-CTLA-4 monoclonal antibodies.
Liu C; Yu C; Yang Y; Cui Y; Zhang F; Wang L; Wang J
Int Immunopharmacol; 2021 Dec; 101(Pt A):108277. PubMed ID: 34773758
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel reporter gene assay to evaluate antibody-dependent cellular phagocytosis for anti-CD20 therapeutic antibodies.
Liu C; Yu C; Yang Y; Huang J; Yu X; Duan M; Wang L; Wang J
Int Immunopharmacol; 2021 Nov; 100():108112. PubMed ID: 34521023
[TBL] [Abstract][Full Text] [Related]
4. A robust reporter assay for the determination of the bioactivity of IL-4R-targeted therapeutic antibodies.
Yu X; Yu C; Wang K; Liu C; Wang L; Wang J
J Pharm Biomed Anal; 2021 May; 199():114033. PubMed ID: 33774455
[TBL] [Abstract][Full Text] [Related]
5. Development of a robust reporter gene assay for measuring the bioactivity of OX40-targeted therapeutic antibodies.
Li M; Wang L; Yu C; Wang J
Luminescence; 2021 Jun; 36(4):885-893. PubMed ID: 33382183
[TBL] [Abstract][Full Text] [Related]
6. Development of a robust reporter gene based assay for the bioactivity determination of IL-5-targeted therapeutic antibodies.
Fu Z; Yu C; Wang L; Gao K; Xu G; Wang W; Cao J; Wang J
J Pharm Biomed Anal; 2018 Jan; 148():280-287. PubMed ID: 29059618
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a reliable cell-based reporter gene assay for measuring bioactivities of therapeutic anti-interleukin-23 monoclonal antibodies.
Huang J; Wang L; Yu C; Fu Z; Liu C; Zhang H; Wang K; Guo X; Wang J
Int Immunopharmacol; 2020 Aug; 85():106647. PubMed ID: 32504997
[TBL] [Abstract][Full Text] [Related]
8. Measuring the bioactivity of anti-IL-6/anti-IL-6R therapeutic antibodies: presentation of a robust reporter gene assay.
Yu C; Cao J; Wang L; Yang Y; Ni Y; Wang J
Anal Bioanal Chem; 2018 Nov; 410(27):7067-7075. PubMed ID: 30178083
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of a reporter gene assay for bioactivity determination of Anti-CGRP monoclonal antibodies.
Guo X; Yu C; Wang L; Zhang F; Wang K; Huang J; Wang J
Anal Biochem; 2021 Dec; 634():114291. PubMed ID: 34161831
[TBL] [Abstract][Full Text] [Related]
10. A reporter gene assay for measuring the bioactivity of anti-LAG-3 therapeutic antibodies.
Wang L; Yu C; Wang K; Wang J
Luminescence; 2020 Dec; 35(8):1408-1415. PubMed ID: 32598535
[TBL] [Abstract][Full Text] [Related]
11. A robust and stable reporter gene bioassay for anti-IgE antibodies.
Guo S; Yu C; Wang Y; Zhang F; Cao J; Zheng C; Wang L
Anal Bioanal Chem; 2020 Mar; 412(8):1901-1914. PubMed ID: 32030491
[TBL] [Abstract][Full Text] [Related]
12. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
Phillips GD; Fields CT; Li G; Dowbenko D; Schaefer G; Miller K; Andre F; Burris HA; Albain KS; Harbeck N; Dieras V; Crivellari D; Fang L; Guardino E; Olsen SR; Crocker LM; Sliwkowski MX
Clin Cancer Res; 2014 Jan; 20(2):456-68. PubMed ID: 24097864
[TBL] [Abstract][Full Text] [Related]
13. Development of a robust reporter gene-based assay for the bioactivity determination of recombinant human follicle stimulating hormone (rhFSH) pharmaceutical products.
Wang LY; Liang CG; Yang HM; Li J; Li ZJ; Zhang H; Lv P; Li Y; Wang JZ
J Pharm Biomed Anal; 2020 Jan; 177():112855. PubMed ID: 31561061
[TBL] [Abstract][Full Text] [Related]
14. In vitro assessment of the effects of anti-HER2 monoclonal antibodies on proliferation of HER2-overexpressing breast cancer cells.
Tahmasebi F; Kazemi T; Amiri MM; Khoshnoodi J; Mahmoudian J; Bayat AA; Jeddi-Tehrani M; Rabbani H; Shokri F
Immunotherapy; 2014; 6(1):43-9. PubMed ID: 24341883
[TBL] [Abstract][Full Text] [Related]
15. HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".
Menéndez JA; Vázquez-Martín A; Ropero S; Colomer R; Lupu R
Clin Transl Oncol; 2006 Nov; 8(11):812-20. PubMed ID: 17134970
[TBL] [Abstract][Full Text] [Related]
16. Construction and evaluation of a novel humanized HER2-specific chimeric receptor.
Sun M; Shi H; Liu C; Liu J; Liu X; Sun Y
Breast Cancer Res; 2014 Jun; 16(3):R61. PubMed ID: 24919843
[TBL] [Abstract][Full Text] [Related]
17. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
18. HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.
de Goeij BE; Peipp M; de Haij S; van den Brink EN; Kellner C; Riedl T; de Jong R; Vink T; Strumane K; Bleeker WK; Parren PW
MAbs; 2014; 6(2):392-402. PubMed ID: 24492309
[TBL] [Abstract][Full Text] [Related]
19. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
20. Pertuzumab for the treatment of breast cancer.
Robert M; Frenel JS; Bourbouloux E; Berton Rigaud D; Patsouris A; Augereau P; Gourmelon C; Campone M
Expert Rev Anticancer Ther; 2020 Feb; 20(2):85-95. PubMed ID: 30884986
[No Abstract] [Full Text] [Related]
[Next] [New Search]
